A Single-Arm Phase II Study of Alemtuzumab in Combination With High-Dose Methylprednisolone in CLL Patients With p53 Deletion

This study is not yet open for participant recruitment.

Study NCT00292760 Information provided by Royal Marsden NHS Foundation Trust

First Received: February 15, 2006 Last Updated: October 12, 2006 History of Changes

No Study Results Posted for this Study

Study Status:	This study is not yet open for participant recruitment.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given